Mesenchymal Stem Cell Selection via Biomaterial Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MSC-based therapies face low engraftment rates due to poor migratory activities of undifferentiated cells, particularly mesenchymal stem cells (MSCs), which limits their effectiveness in regenerative medicine, and existing methods to enhance engraftment are invasive, costly, or address only heterogeneity issues.
Innovation Solution
A method involving the encapsulation of MSCs in a biomaterial barrier, such as collagen, to select subpopulations with enhanced migratory activities, which are then induced to migrate, resulting in improved spontaneous and directional migration and increased engraftment rates to injured tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If MSCs are injected systemically to treat multiple tissues, then the treatment coverage is improved, but the engraftment rate deteriorates due to poor migratory activities
Solution Approach 1:
The patent applies preliminary action by pre-treating MSCs with chemoattractants (such as SDF-1) before systemic injection to enhance their migratory capacity in advance. This pre-conditioning ensures that when cells are injected systemically to treat multiple tissues, they possess enhanced migratory activities from the outset, thereby maintaining both broad treatment coverage and high engraftment rates at target sites
2Reliability
If local injection is used to improve engraftment in target tissue, then the engraftment rate is improved, but the invasiveness and inapplicability to multiple tissues worsens
Solution Approach 1:
The patent applies universality by developing a chemoattractant pre-treatment method that can be applied regardless of injection route (systemic or local) or target tissue type. This universal approach allows the same pre-conditioning protocol to enhance engraftment whether cells are injected locally into a single organ or systemically to treat multiple tissues simultaneously, thereby eliminating the need to choose between local and systemic approaches
3Speed
If MSCs are treated with chemoattractants to enhance responsiveness, then the directional migration is improved, but the cost and complexity worsens
Solution Approach 1:
The patent applies parameter changes by optimizing chemoattractant treatment parameters such as concentration, treatment duration, and timing to achieve effective directional migration enhancement while minimizing complexity. By carefully controlling these parameters (e.g., using physiological concentrations of SDF-1 and standardized treatment protocols), the method achieves improved cell homing without requiring complex delivery systems or multiple treatment steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selected MSC subpopulations demonstrate enhanced migratory activities and increased engraftment rates to injured tissues, improving the efficacy of cell-based therapies with better survival and functional integration, while maintaining self-renewal capacity and differentiating potential.
Implementation Method 1
A method involving the encapsulation of MSCs in a biomaterial barrier, such as collagen
Implementation Method 2
directional movement of stem cells towards gradients of chemoattractants and cytokines induced by tissue injuries
Data Source
AI summary
A method is provided to functionally select cells with enhanced characteristics relevant to cell engraftment, including both spontaneous migration and directional migration towards specific chemo-attractants. The cells are preferably undifferentiated cells, such as mesenchymal stem cells. The method involves entrapping or encapsulating the cells in a biomaterial barrier, optionally inducing cell migration, and selecting cells that migrated through the barrier. The cells selected by this method have better migratory activities and enhanced in vivo engraftment to injured tissues when they are supplemented systemically.